Haematology

News

Survival data graph from the DREAMM-7 trial

ASH: Blenrep ups survival by 42% in multiple myeloma trial

GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.

News

ASH: Regeneron plays its PNH hand

Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.

News

ASH: MSD’s ROR1 drug hits the target in first-line lymphoma

The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.

News

Pfizer bags EU okay for haemophilia drug Hympavzi

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU

News

Syndax gets FDA okay for first-in-class leukaemia drug

A few days after a disappointing clinical trial readout for Syndax Pharma's Revuforj in one form of leukaemia, the company has claimed FDA approval in another.

News

Bone marrow aspirate showing the histologic correlate of multiple myeloma under the microscope, H&E stain

GSK hails survival data with revived myeloma drug Blenrep

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached stat

ASH: Blenrep ups survival by 42% in multiple myeloma trial

ASH: Regeneron plays its PNH hand

ASH: MSD’s ROR1 drug hits the target in first-line lymphoma

Pfizer bags EU okay for haemophilia drug Hympavzi

Syndax gets FDA okay for first-in-class leukaemia drug

GSK hails survival data with revived myeloma drug Blenrep

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Haematology

Editor's Picks